For the Inventor, By the Inventor

Enter assignee name

Lytix Biopharma As

USPTO Granted Patents = 17

EPO Patents = 9

Forward Citations = 34

Loading Chart...

Loading Chart...

29 inventors (with patents filed for the assignee):

John Sigurd Svendsen (13 out of 17 patents)

Øystein Rekdal (9 out of 11 patents)

Wenche Stensen (8 out of 10 patents)

4. Oystein Rekdal (6 out of 7 patents)

5. Bengt Erik Haug (4 out of 4 patents)

6. Baldur Sveinbjørnsson (4 out of 4 patents)

7. Liv Marie Eike (3 out of 3 patents)

8. John Sigurd Mjoen Svendsen (3 out of 3 patents)

9. Morten Bøhmer Strøm (3 out of 4 patents)

10. Istvan Marko (3 out of 3 patents)

11. Merete Linchausen Skar (3 out of 3 patents)

12. Frederick Alan Leeson (3 out of 4 patents)

13. Ketil Camilio (2 out of 2 patents)

14. Baldur Sveinbjornsson (2 out of 2 patents)

15. Laurence Zitvogel (2 out of 2 patents)

17 patents: Sort by Forward Citations

1. 12239686 - Immune checkpoint inhibitor combinations (2025-03-04),

2. 11123398 - Chemotherapeutic combinations of cationic antimicrobial peptides and chemotherapeutics (2021-09-21),

3. 11083774 - Immune checkpoint inhibitor combinations (2021-08-10),

4. 10231954 - Neurodegenerative therapies (2019-03-19),

5. 9556223 - Antimicrobial compounds (2017-01-31),

6. 9241968 - Nonapeptide with anti-tumour activity (2016-01-26),

7. 9212202 - Methods of peptide modification (2015-12-15),

8. 9115169 - Method of treating tumors (2015-08-25),

9. 9109048 - Inhibition of tumor growth (2015-08-18),

10. 9085608 - Treatment of biofilms (2015-07-21),

11. 8809280 - Therapeutic peptides (2014-08-19),

12. 8598114 - Antimicrobial compounds (2013-12-03),

13. 8283315 - Inhibition of tumour growth (2012-10-09),

14. 8143211 - Bioactive peptides (2012-03-27),

15. 8048852 - Antimicrobial compounds and formulations (2011-11-01),

Lytix Biopharma is a Norwegian biotechnology company focused on developing innovative cancer therapeutics. The company is dedicated to harnessing the power of the immune system to target and destroy cancer cells. Lytix Biopharma's lead product candidate is LTX-315, a novel oncolytic peptide that has shown promising results in preclinical studies. The company is committed to advancing LTX-315 through clinical development and bringing it to market to improve outcomes for cancer patients.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

17 Patents

#1 in Tromso

#91 in Norway

#34,854 in the World

Lytix Biopharma As

Forward Citations = 34

29 inventors:

John Sigurd Svendsen (13 out of 17 patents)

Øystein Rekdal (9 out of 11 patents)

Wenche Stensen (8 out of 10 patents)

4. Oystein Rekdal (6 out of 7 patents)

5. Bengt Erik Haug (4 out of 4 patents)

Please report any incorrect information to support@idiyas.com

Loading…